

**A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED, PARALLEL-GROUP PILOT STUDY TO
INVESTIGATE THE EFFECTS OF HUMIC ACID ON
SYMPTOMS OF INFLUENZA**

FINAL REPORT SUMMARY ABSTRACT

Prepared By:

Laub BioChemicals Corporation

September 23, 2010

Study Carried Out By:

KGK Synergize, Inc.
255 Queens Avenue
Suite 1440
London, Ontario
Canada N6A 5R8
Telephone: 519-438-9374
Facsimile: 519-438-8314

January 27, 2010 – July 19, 2010

Medical Director
Dale Wilson, MD

Objectives:

The primary objective of this Clinical Trial was to assess the efficacy of Laub BioChemicals Corporation's VFI Humic Acid[®] on flu symptoms as assessed by the alleviation of symptoms after 7 and 14 days of treatment in adults with influenza A or B.

Methodology:

This was a multi-center, randomized, double-blind, placebo-controlled, parallel-group Clinical Trial with a single 14-day treatment period to assess the efficacy of VFI Humic Acid[®] on flu symptoms in adults. The Trial was conducted at two sites in the US: Advanced Research Institute, Inc. (Trinity, FL) and Vertitas Research Corp. (Miami Lakes, FL). The Trial was managed by KGK Synergize, Inc.

Results:

Subjects on VFI Humic Acid[®] reported higher scores for cough, fever, runny nose, stuffy nose, aches, chills, sneezing, earaches and fatigue on Day 1. After supplementation for 7 days with VFI Humic Acid[®], symptom scores improved by a greater percentage than did those for Subjects taking Placebo for the same duration for cough (61.9% vs. 36.8%), fever (91.7% vs. 81.8%), runny nose (66.7% vs. 62.5%), stuffy nose (66.7% vs. 62.5%), aches (86.4% vs. 62.5%), chills (91.7% vs. 66.7%), sneezing (70.6% vs. 61.5%) and fatigue (80.0% vs. 54.5%). Mean scores for Subjects on VFI Humic Acid[®] were also lower than for those on Placebo after 7 days of treatment for cough, fever, aches, chills and fatigue in spite of being worse than Placebo on Day 1.

Conclusions:

VFI Humic Acid[®] demonstrated clinically-noteworthy efficacy on influenza viral infection in the 2010 flu season by improving flu-related symptoms, cytokine response, immune-system modulators CD4+ and CD8+, and VAS scores when provided as 6 x 250-mg tablets daily for 14 days within the demographic of Subjects studied.